ReviewCritical care (London, England)2007
Recombinant human activated protein C: current insights into its mechanism of action.
Review in Critical care (London, England), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 62 citations in OpenAlex.
- Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock.Critical care (London, England) · 2010Trial
- The contact pathway and sepsis.Research and practice in thrombosis and haemostasis · 2019Review
- UM171 induces a homeostatic inflammatory-detoxification response supporting human HSC self-renewal.PloS one · 2019Article
- Why activated protein C was not successful in severe sepsis and septic shock: are we still tilting at windmills?Current infectious disease reports · 2013Article
- Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center.Therapeutics and clinical risk management · 2013Article
- Live liver donors: Are they at a higher risk for post-operative thrombotic complications?World journal of transplantation · 2012Article
- Systemic versus localized coagulation activation contributing to organ failure in critically ill patients.Seminars in immunopathology · 2012Review
- Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study.Critical care (London, England) · 2011Article
- The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.Nature reviews. Drug discovery · 2011Review
- Adjunct therapy for sepsis: how early?Current infectious disease reports · 2010Article
- The resuscitation package in sepsis.Current infectious disease reports · 2010Article
- Use of recombinant human activated protein C in nonmenstrual staphylococcal toxic shock syndrome.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2010Article
- Update on the role of Toll-like receptors during bacterial infections and sepsis.Wiener medizinische Wochenschrift (1946) · 2010Review
- Recombinant human activated protein C in acute lung injury: what is the role of bronchial circulation?Critical care (London, England) · 2009Review
- Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort.Critical care (London, England) · 2009Article
- Introduction: severe sepsis and drotrecogin alfa (activated).Critical care (London, England) · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Impairment of the protein C pathway plays a central role in the pathogenesis of sepsis. Administration of recombinant human activated protein C (rhAPC) may correct the dysregulated anticoagulant mechanism and prevent propagation of thrombin generation and formation of microvascular thrombosis. Furthermore, it may simultaneously modulate the inflammatory response. It is likely that the beneficial effect of rhAPC observed in experimental and clinical studies of severe sepsis results from a combination of mechanisms that modulate the entangled processes of coagulation and inflammation. This review presents an analysis of the various mechanisms of action of rhAPC in sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.